TSC2 and primitive neuroectodermal tumor: Loss of function mutations of the tumour suppressor TSC1 are seen in bladder cancer[42], while 25 different TSC2 mutation sites, mainly in or near the RAP-GAP domain, have been reported in pancreatic neuroendocrine tumours (PNET)[43].